临床试验

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

NCT：NCT06733922 · RECRUITING

NCT编号NCT06733922

状态RECRUITING

开始日期2024-11-27

完成时间2028-11-30

SponsorNovartis Pharmaceuticals (INDUSTRY)

First posted2024-12-13

Last updated2026-05-15

简要摘要

The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。